These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

688 related articles for article (PubMed ID: 22498306)

  • 1. MicroRNA-199a targets CD44 to suppress the tumorigenicity and multidrug resistance of ovarian cancer-initiating cells.
    Cheng W; Liu T; Wan X; Gao Y; Wang H
    FEBS J; 2012 Jun; 279(11):2047-59. PubMed ID: 22498306
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cisplatin targets the stromal cell-derived factor-1-CXC chemokine receptor type 4 axis to suppress metastasis and invasion of ovarian cancer-initiating cells.
    Yu ZH; Liu T; Zhao YH; Huang YY; Gao YT
    Tumour Biol; 2014 May; 35(5):4637-44. PubMed ID: 24408020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MiR-199a-5p represses the stemness of cutaneous squamous cell carcinoma stem cells by targeting Sirt1 and CD44ICD cleavage signaling.
    Lu RH; Xiao ZQ; Zhou JD; Yin CQ; Chen ZZ; Tang FJ; Wang SH
    Cell Cycle; 2020 Jan; 19(1):1-14. PubMed ID: 31809227
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RhoC is a major target of microRNA-93-5P in epithelial ovarian carcinoma tumorigenesis and progression.
    Chen X; Chen S; Xiu YL; Sun KX; Zong ZH; Zhao Y
    Mol Cancer; 2015 Feb; 14(1):31. PubMed ID: 25649143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.
    Kong Y; Bai PS; Sun H; Nan KJ; Chen NZ; Qi XG
    Int J Biochem Cell Biol; 2012 Dec; 44(12):2321-32. PubMed ID: 22903020
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Upregulation of miR-199a/b contributes to cisplatin resistance via Wnt/β-catenin-ABCG2 signaling pathway in ALDHA1
    Chen B; Zhang D; Kuai J; Cheng M; Fang X; Li G
    Tumour Biol; 2017 Jun; 39(6):1010428317715155. PubMed ID: 28639895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8.
    Cui Y; Wu F; Tian D; Wang T; Lu T; Huang X; Zhang P; Qin L
    Oncol Rep; 2018 Apr; 39(4):1649-1657. PubMed ID: 29436681
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hypoxia-related microRNA miR-199a-3p displays tumor suppressor functions in ovarian carcinoma.
    Kinose Y; Sawada K; Nakamura K; Sawada I; Toda A; Nakatsuka E; Hashimoto K; Mabuchi S; Takahashi K; Kurachi H; Lengyel E; Kimura T
    Oncotarget; 2015 May; 6(13):11342-56. PubMed ID: 25839163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-873 mediates multidrug resistance in ovarian cancer cells by targeting ABCB1.
    Wu DD; Li XS; Meng XN; Yan J; Zong ZH
    Tumour Biol; 2016 Aug; 37(8):10499-506. PubMed ID: 26850595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ABCG2 is a potential marker of tumor-initiating cells in breast cancer.
    Sicchieri RD; da Silveira WA; Mandarano LR; de Oliveira TM; Carrara HH; Muglia VF; de Andrade JM; Tiezzi DG
    Tumour Biol; 2015 Dec; 36(12):9233-43. PubMed ID: 26091795
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-155 is a novel suppressor of ovarian cancer-initiating cells that targets CLDN1.
    Qin W; Ren Q; Liu T; Huang Y; Wang J
    FEBS Lett; 2013 May; 587(9):1434-9. PubMed ID: 23523916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-181a enhances drug sensitivity in mitoxantone-resistant breast cancer cells by targeting breast cancer resistance protein (BCRP/ABCG2).
    Jiao X; Zhao L; Ma M; Bai X; He M; Yan Y; Wang Y; Chen Q; Zhao X; Zhou M; Cui Z; Zheng Z; Wang E; Wei M
    Breast Cancer Res Treat; 2013 Jun; 139(3):717-30. PubMed ID: 23780685
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exploiting a novel miR-519c-HuR-ABCG2 regulatory pathway to overcome chemoresistance in colorectal cancer.
    To KK; Leung WW; Ng SS
    Exp Cell Res; 2015 Nov; 338(2):222-31. PubMed ID: 26386386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different Effects of BORIS/CTCFL on Stemness Gene Expression, Sphere Formation and Cell Survival in Epithelial Cancer Stem Cells.
    Alberti L; Losi L; Leyvraz S; Benhattar J
    PLoS One; 2015; 10(7):e0132977. PubMed ID: 26185996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-199a-3p targets stemness-related and mitogenic signaling pathways to suppress the expansion and tumorigenic capabilities of prostate cancer stem cells.
    Liu R; Liu C; Zhang D; Liu B; Chen X; Rycaj K; Jeter C; Calhoun-Davis T; Li Y; Yang T; Wang J; Tang DG
    Oncotarget; 2016 Aug; 7(35):56628-56642. PubMed ID: 27447749
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem-like cells from human prostate cancer cell lines 22RV1.
    Liu T; Xu F; Du X; Lai D; Liu T; Zhao Y; Huang Q; Jiang L; Huang W; Cheng W; Liu Z
    Mol Cell Biochem; 2010 Jul; 340(1-2):265-73. PubMed ID: 20224986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sonic hedgehog-glioma associated oncogene homolog 1 signaling enhances drug resistance in CD44(+)/Musashi-1(+) gastric cancer stem cells.
    Xu M; Gong A; Yang H; George SK; Jiao Z; Huang H; Jiang X; Zhang Y
    Cancer Lett; 2015 Dec; 369(1):124-33. PubMed ID: 26276718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of characteristics of CD44+CD117+ ovarian cancer stem cells in three dimensional basement membrane extract scaffold versus two dimensional monocultures.
    Chen J; Wang J; Chen D; Yang J; Yang C; Zhang Y; Zhang H; Dou J
    BMC Cell Biol; 2013 Jan; 14():7. PubMed ID: 23368632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-98-5p inhibits gastric cancer cell stemness and chemoresistance by targeting branched-chain aminotransferases 1.
    Zhan P; Shu X; Chen M; Sun L; Yu L; Liu J; Sun L; Yang Z; Ran Y
    Life Sci; 2021 Jul; 276():119405. PubMed ID: 33798550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EGCG inhibits CSC-like properties through targeting miR-485/CD44 axis in A549-cisplatin resistant cells.
    Jiang P; Xu C; Chen L; Chen A; Wu X; Zhou M; Haq IU; Mariyam Z; Feng Q
    Mol Carcinog; 2018 Dec; 57(12):1835-1844. PubMed ID: 30182373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.